Oncotracker, Inc., Corporation just had published form D regarding $2.00 million equity and debt financing. The date of first sale was 2015-03-23. Oncotracker was able to sell $1.12 million so far. That is 56.00% of the financing offer. The total offering amount was $2.00 million. The offering form was filed on 2016-11-10. The reason for the financing was: unspecified. The fundraising still has about $880,000 more and is not closed yet. We have to wait more to see if the offering will be fully taken.
Oncotracker is based in California. The company’s business is not disclosed. The SEC form was submitted by Geoffrey M Gee Treasurer and Secretary. The company was incorporated in 2014. The filler’s address is: 9201 Sunset Boulevard, Suite 300, West Hollywood, Ca, California, 90069. James Berenson is the related person in the form and it has address: 9201 Sunset Boulevard, Suite 300, West Hollywood, Ca, California, 90069. Link to Oncotracker Filing: 000163833216000002.
Analysis of Oncotracker Offering
On average, firms in the not disclosed sector, sell 67.77% of the total offering amount. Oncotracker sold 56.00% of the offering. The fundraising is still open. The average fundraising size for companies in all industries in our database is $3.05 million. The offering was 63.28% smaller than the average of $3.05 million. Of course this should not be taken as negative. Startups get financed for a variety of reasons and needs. The minimum investment for this offering was set at $0. If you know more about the reasons for the fundraising, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Oncotracker Also
The Form D signed by Geoffrey M Gee might help Oncotracker, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.